Literature DB >> 27068171

Management of Inflammatory Bowel Disease During Pregnancy.

Ariella Bar-Gil Shitrit1, Sorina Grisaru-Granovsky2, Ami Ben Ya'acov3, Eran Goldin3.   

Abstract

Inflammatory bowel disease (IBD) usually affects women during their reproductive years and many concerns arise among these young patients. Pre-pregnancy consultation with a multi-disciplinary team is very important. The team should make patients aware of the critical importance of ensuring that conception occurs during a period of disease remission. Conception during an IBD flare-up results in disease activity or even exacerbates disease in two-thirds of women. Exacerbation of the disease is associated with increased frequency of maternal and fetal complications. Drug therapy constitutes a considerable source of patient anxiety but most drugs used for treating IBD are considered safe. Therefore, continuing pharmacological therapy during pregnancy is necessary to maintain disease control. Optimization of pre-conception nutritional status and smoking cessation are also emphasized. The general guideline for most patients, except for active perianal disease patients, is to aim for vaginal delivery in the absence of obstetric contraindications. Consistent, ongoing follow-up, as detailed in this review, should allay the anxieties and fears surrounding continuing immunosuppressive drugs during pregnancy, allowing each patient to attain the optimal conditions for achieving her goal of holding a healthy baby.

Entities:  

Keywords:  Inflammatory bowel disease; Medications; Obstetric complications; Pregnancy; Remission

Mesh:

Substances:

Year:  2016        PMID: 27068171     DOI: 10.1007/s10620-016-4139-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  102 in total

1.  Teratogen update: azathioprine and 6-mercaptopurine.

Authors:  Janine E Polifka; J M Friedman
Journal:  Teratology       Date:  2002-05

2.  Fertility and pregnancy in inflammatory bowel disease.

Authors:  M Hudson; G Flett; T S Sinclair; P W Brunt; A Templeton; N A Mowat
Journal:  Int J Gynaecol Obstet       Date:  1997-08       Impact factor: 3.561

Review 3.  American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy.

Authors:  Uma Mahadevan; Sunanda Kane
Journal:  Gastroenterology       Date:  2006-07       Impact factor: 22.682

4.  Corticosteroid use during pregnancy and risk of orofacial clefts.

Authors:  Anders Hviid; Ditte Mølgaard-Nielsen
Journal:  CMAJ       Date:  2011-04-11       Impact factor: 8.262

5.  Maternal inflammatory bowel disease has short and long-term effects on the health of their offspring: a multicenter study in Israel.

Authors:  Iris Dotan; Arik Alper; Daniel Rachmilewitz; Eran Israeli; Shmuel Odes; Irit Chermesh; Timna Naftali; Gerald Fraser; Ariella Bar-Gil Shitrit; Vardit Peles; Shimon Reif
Journal:  J Crohns Colitis       Date:  2012-10-02       Impact factor: 9.071

6.  Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites.

Authors:  G Järnerot; M B Into-Malmberg; E Esbjörner
Journal:  Scand J Gastroenterol       Date:  1981       Impact factor: 2.423

7.  Azathioprine treatment during lactation.

Authors:  L A Christensen; J F Dahlerup; M J Nielsen; J F Fallingborg; K Schmiegelow
Journal:  Aliment Pharmacol Ther       Date:  2008-08-30       Impact factor: 8.171

8.  Female fecundity before and after operation for familial adenomatous polyposis.

Authors:  K Ø Olsen; S Juul; S Bülow; H J Järvinen; A Bakka; J Björk; T Oresland; S Laurberg
Journal:  Br J Surg       Date:  2003-02       Impact factor: 6.939

9.  Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.

Authors:  Zuzana Zelinkova; Cokkie van der Ent; Karlien F Bruin; Onno van Baalen; Hestia G Vermeulen; Herman J T Smalbraak; Rob J Ouwendijk; Aad C Hoek; Sjoerd D van der Werf; Ernst J Kuipers; C Janneke van der Woude
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-25       Impact factor: 11.382

10.  Cyclosporine excretion into breast milk.

Authors:  Myla E Moretti; Michael Sgro; David W Johnson; Reg S Sauve; Mary J Woolgar; Anna Taddio; Zul Verjee; Esther Giesbrecht; Gideon Koren; Shinya Ito
Journal:  Transplantation       Date:  2003-06-27       Impact factor: 4.939

View more
  3 in total

1.  Dietary Patterns in women with Inflammatory Bowel Disease and Risk of Adverse Pregnancy Outcomes: Results from The Norwegian Mother and Child Cohort Study (MoBa).

Authors:  Thea Myklebust-Hansen; Geir Aamodt; Margaretha Haugen; Anne Lise Brantsæter; Morten H Vatn; May-Bente Bengtson
Journal:  Inflamm Bowel Dis       Date:  2017-12-19       Impact factor: 5.325

2.  Thiopurine Therapy for Inflammatory Bowel Disease During Pregnancy Is Not Associated with Anemia in the Infant.

Authors:  Benjamin Koslowsky; Chen Sadeh; Sorina Grisaru-Granovsky; Hagit Miskin; Eran Goldin; Ariella Bar-Gil Shitrit
Journal:  Dig Dis Sci       Date:  2019-02-28       Impact factor: 3.199

3.  Fecal Lactoferrin and Other Stool Markers during Normal Pregnancy and in Inflammatory Bowel Diseases: A Prospective Study and Review of the Literature.

Authors:  James M Gray; Kristin Knight; Vu Q Nguyen; Marrieth G Rubio; Lauren Irby; James H Boone; Dario Sorrentino
Journal:  Inflamm Intest Dis       Date:  2020-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.